Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (471-480 of 523) with videos related to

Pageof 53
Sort By:
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Journal of the American Academy of Dermatology|June 5, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsAlan Menter, Neil J Korman, Craig A Elmets, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|December 4, 2023
Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativaKristina Navrazhina, Yael Renert-Yuval, Saakshi Khattri, et al.
Pageof 53

Showing results (471-480 of 523) with videos related to

Sort By:
Pageof 53
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Journal of the American Academy of Dermatology|June 5, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsAlan Menter, Neil J Korman, Craig A Elmets, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|December 4, 2023
Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativaKristina Navrazhina, Yael Renert-Yuval, Saakshi Khattri, et al.
Pageof 53